The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part II

참고문헌 (103)

1. Baber RJ, "2016 IMS Recommendations on women’s midlife health and menopause hormone therapy", Climacteric, 19, pp.109~150 (2016)
2. Wells G, "Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women", Endocr Rev, 23, pp.529~539 (2002)
3. Trial P, "Effects of hormone therapy on bone mineral density : results from the postmenopausal estrogen", progestin interventions(PEPI)trial. The Writing Group for the PEPI, 1996, pp.276, 1389~1396
4. Jackson RD, "Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy : results from the women’s health initiative randomized trial", J Bone Miner Res, 21, pp.817~828 (2006)
5. Cauley JA, "Effects of estrogen plus progestin on risk of fracture and bone mineral density : the Women’s Health Initiative randomized trial", JAMA, 290, pp.1729~1738 (2003)
6. McClung M, "Management of osteoporosis in postmenopausal women : the 2021 position statement of The North American Menopause Society", Menopause, 28, pp.973~997 (2021)
7. Eastell R, "Pharmacological management of osteoporosis in postmenopausal women : an endocrine society clinical practice guideline", J Clin Endocrinol Metab, 104, pp.1595~1622 (2019)
8. Cummings SR, "The effects of tibolone in older postmenopausal women", N Engl J Med, 359, pp.697~708 (2008)
9. Gallagher JC, "Effect of conjugated estrogens", bazedoxifene on postmenopausal bone loss : pooled analysis of two randomized trials, 2016, pp.23, 1083~1091
10. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women’s Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
11. Lindsay R, "Efficacy of tissue-selective estrogen complex of bazedoxifene", conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women, 2009, pp.92, 1045~1052
12. Heaney RP, "Raloxifene and estrogen : comparative bone-remodeling kinetics", J Clin Endocrinol Metab, 82, pp.3425~3429 (1997)
13. Ettinger B, "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene : results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation(MORE)Investigators", JAMA, 282, pp.637~645 (1999)
14. Silverman SL, "Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis : results from a 3-year, randomized, placebo-, and active-controlled clinical trial", J Bone Miner Res, 23, pp.1923~1934 (2008)
15. Vogel VG, "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes : the NSABP Study of Tamoxifen and Raloxifene(STAR)P-2 trial", JAMA, 295, pp.2727~2741 (2006)
16. Collins P, "Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial : results of subgroup analyses by age and other factors", Circulation, 119, pp.922~930 (2009)
17. Lim YW, "The medical treatment of osteoporosis", J Korean Hip Soc, 21, pp.211~218 (2009)
18. Park HM, "Current use of drugs for osteoporosis in Korea", Korean J Obstet Gynecol, 53, pp.152~159 (2010)
19. Kang BM, "Comparison of anti-osteoporotic medications and alternatives", Korean J Obstet Gynecol, 49, pp.2459~2472 (2006)
20. Black DM, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group", Lancet, 348, pp.1535~1541 (1996)
21. Cummings SR, "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures : results from the Fracture Intervention Trial", JAMA, 280, pp.2077~2082 (1998)
22. Black DM, "Fracture risk reduction with alendronate in women with osteoporosis : the Fracture Intervention Trial. FIT Research Group", J Clin Endocrinol Metab, 85, pp.4118~4124 (2000)
23. Harris ST, "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis : a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy(VERT)Study Group", JAMA, 282, pp.1344~1352 (1999)
24. Mellström DD, "Seven years of treatment with risedronate in women with postmenopausal osteoporosis", Calcif Tissue Int, 75, pp.462~468 (2004)
25. Chesnut CH 3rd, "Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis", J Bone Miner Res, 19, pp.1241~1249 (2004)
26. Park YS, "Diagnosis and treatment of osteoporosis", J Korean Med Assoc, 55, pp.1083~1094 (2012)
27. Yoon SH, "Current treatment of postmenopausal osteoporosis", Korean J Obstet Gynecol, 48, pp.844~856 (2005)
28. Reid IR, "Intravenous zoledronic acid in postmenopausal women with low bone mineral density", N Engl J Med, 346, pp.653~661 (2002)
29. Lapi F, "Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures", Osteoporos Int, 24, pp.697~705 (2013)
30. Lewiecki EM, "Two-year treatment with denosumab(AMG 162)in a randomized phase 2 study of postmenopausal women with low BMD", J Bone Miner Res, 22, pp.1832~1841 (2007)
31. Miller PD, "Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy : a randomized blinded phase 2 clinical trial", Bone, 43, pp.222~229 (2008)
32. Bone HG, "Effects of denosumab on bone mineral density and bone turnover in postmenopausal women", J Clin Endocrinol Metab, 93, pp.2149~2157 (2008)
33. Brown JP, "Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass : a randomized, blinded, phase 3 trial", J Bone Miner Res, 24, pp.153~161 (2009)
34. Kendler DL, "Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy", J Bone Miner Res, 25, pp.72~81 (2010)
35. Cummings SR, "Denosumab for prevention of fractures in postmenopausal women with osteoporosis", N Engl J Med, 361, pp.756~765 (2009)
36. Bone HG, "10 years of denosumab treatment in post menopausal women with osteoporosis : results from the phase 3randomised FREEDOM trial and open-label extension", Lancet Diabetes Endocrinol, 5, pp.513~523 (2017)
37. Barrionuevo P, "Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women : a network meta-analysis", J Clin Endocrinol Metab, 104, pp.1623~1630 (2019)
38. Camacho PM, "American Association of Clinical Endocrinologists", American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2020 update, 2020, pp.26, 1~46
39. Kanis JA, "European guidance for the diagnosis and management of osteoporosis in postmenopausal women", Osteoporos Int, 30, pp.3~44 (2019)
40. Cosman F, "Clinician’s guide to prevention and treatment of osteoporosis", Osteoporos Int, 25, pp.2359~2381 (2014)
41. Neer RM, "Effect of parathyroid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis", N Engl J Med, 344, pp.1434~1441 (2001)
42. Lindsay R, "Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis", Osteoporos Int, 20, pp.943~948 (2009)
43. Kendler DL, "Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis(VERO) : a multicentre, double-blind, double-dummy, randomised controlled trial", Lancet, 391, pp.230~240 (2018)
44. Fan G, "Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients : a metaanalysis", Medicine (Baltimore), 99, pp.e18964~ (2020)
45. Obermayer-Pietsch BM, "Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment", J Bone Miner Res, 23, pp.1591~1600 (2008)
46. Gilsenan A, "The Forteo Patient Registry linkage to multiple state cancer registries : study design and results from the first 8 years", Osteoporos Int, 29, pp.2335~2343 (2018)
47. Watanabe A, "Osteosarcoma in Sprague-Dawley rats after longterm treatment with teriparatide(human parathyroid hormone(1-34))", J Toxicol Sci, 37, pp.617~629 (2012)
48. Saag KG, "Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis : thirty-six-month results of a randomized, double-blind, controlled trial", Arthritis Rheum, 60, pp.3346~3355 (2009)
49. Miller PD, "Teriparatide : label changes and identifying patients for long-term use", Cleve Clin J Med, 88, pp.489~493 (2021)
50. Leder BZ, "Denosumab and teriparatide transitions in postmenopausal osteoporosis(the DATA-Switch study) : extension of a randomised controlled trial", Lancet, 386, pp.1147~1155 (2015)
51. Moon NH, "Romosozumab : a novel agent in the management of osteoporosis", J Korean Fract Soc, 34, pp.148~153 (2021)
52. Cosman F, "Romosozumab treatment in postmenopausal women with osteoporosis", N Engl J Med, 375, pp.1532~1543 (2016)
53. Lewiecki EM, "One year of romosozumab followed by two years of denosumab maintains fracture risk reductions : results of the FRAME extension study", J Bone Miner Res, 34, pp.419~428 (2019)
54. Cosman F, "Levels of improvements in bone mineral density in postmenopausal women with osteoporosis treated with romosozumab : a post hoc analysis of the arch phase 3 trial", Osteoporosis Int, 30(Suppl 2), pp.S732~S733 (2019)
55. Saag KG, "Romosozumab or alendronate for fracture prevention in women with osteoporosis", N Engl J Med, 377, pp.1417~1427 (2017)
56. Langdahl BL, "Romosozumab(sclerostin monoclonal antibody)versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy : a randomised, open-label, phase 3 trial", Lancet, 390, pp.1585~1594 (2017)
57. Paik J, "Romosozumab : a review in postmenopausal osteoporosis", Drugs Aging, 37, pp.845~855 (2020)
58. Lindsay R, "Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis : a randomized, controlled clinical trial", J Clin Endocrinol Metab, 84, pp.3076~3081 (1999)
59. Bone HG, "Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate", Estrogen Study Group, 2000, pp.85, 720~726
60. Lindsay R, "Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis", Lancet, 350, pp.550~555 (1997)
61. Cosman F, "Parathyroid hormone added to established hormone therapy : effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal", J Bone Miner Res, 16, pp.925~931 (2001)
62. Johnell O, "Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis", J Clin Endocrinol Metab, 87, pp.985~992 (2002)
63. Sanad Z, "Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis", Climacteric, 14, pp.369~377 (2011)
64. Vegni FE, "Effects of parathyroid hormone and alendronate alone or in combination in osteoporosis", N Engl J Med, 350, pp.189~192 (2004)
65. Li W, "The efficacy of parathyroid hormone analogues in combination with bisphosphonates for the treatment of osteoporosis : a meta-analysis of randomized controlled trials", Medicine (Baltimore), 94, pp.e1156~ (2015)
66. Lou S, "Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis : a systematic review and meta-analysis of randomized controlled trials", Osteoporos Int, 30, pp.59~70 (2019)
67. in postmenopausal osteoporosis, "J Bone Miner Res", 2011, 503~511
68. Deal C, "Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis : results from a 6-month double-blind placebo-controlled trial", J Bone Miner Res, 20, pp.1905~1911 (2005)
69. Michalská D, "The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis", J Clin Endocrinol Metab, 91, pp.870~877 (2006)
70. Lyu H, "Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use", J Clin Endocrinol Metab, 104, pp.5611~5620 (2019)
71. Miller PD, "Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates", J Clin Endocrinol Metab, 101, pp.3163~3170 (2016)
72. Ettinger B, "Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate", J Bone Miner Res, 19, pp.745~751 (2004)
73. Eastell R, "Sequential treatment of severe postmenopausal osteoporosis after teriparatide : final results of the randomized, controlled European Study of Forsteo(EUROFORS)", J Bone Miner Res, 24, pp.726~736 (2009)
74. Grassi G, "Bisphosphonates after denosumab withdrawal reduce the vertebral fractures incidence", Eur J Endocrinol, 185, pp.387~396 (2021)
75. Kondo H, "Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment", J Bone Miner Metab, 38, pp.894~902 (2020)
76. Anastasilakis AD, "Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial", J Bone Miner Res, 34, pp.2220~2228 (2019)
77. Leder BZ, "Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy", J Bone Miner Res Plus, 2, pp.62~68 (2018)
78. Rittmaster RS, "Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate", J Clin Endocrinol Metab, 85, pp.2129~2134 (2000)
79. "Osteoporos Int", 2004, 992~997
80. Black DM, "One year of alendronate after one year of parathyroid hormone(1-84)for osteoporosis", N Engl J Med, 353, pp.555~565 (2005)
81. Siris ES, "Bone mineral density thresholds for pharmacological intervention to prevent fractures", Arch Intern Med, 164, pp.1108~1112 (2004)
82. Pasco JA, "The population burden of fractures originates in women with osteopenia, not osteoporosis", Osteoporos Int, 17, pp.1404~1409 (2006)
83. Schuit SC, "Fracture incidence and association with bone mineral density in elderly men and women : the Rotterdam Study", Bone, 34, pp.195~202 (2004)
84. Kanis JA, "Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds", Osteoporos Int, 12, pp.989~995 (2001)
85. Kanis JA, "Diagnosis of osteoporosis and assessment of fracture risk", Lancet, 359, pp.1929~1936 (2002)
86. Kanis JA, "Assessment of fracture risk", Osteoporos Int, 16, pp.581~589 (2005)
87. Park EJ, "Prevalence of osteoporosis in the Korean population based on Korea National Health and Nutrition Examination Survey(KNHANES), 2008-2011", Yonsei Med J, 55, pp.1049~1057 (2014)
88. Looker AC, "Prevalence and trends in low femur bone density among older US adults : NHANES 2005-2006 compared with NHANES III", J Bone Miner Res, 25, pp.64~71 (2010)
89. Reid IR, "Fracture prevention with zoledronate in older women with osteopenia", N Engl J Med, 379, pp.2407~2416 (2018)
90. Siris ES, "Effects of risedronate on fracture risk in postmenopausal women with osteopenia", Osteoporos Int, 19, pp.681~686 (2008)
91. Kanis JA, "Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis : a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial", Bone, 33, pp.293~300 (2003)
92. Cruz-Jentoft AJ, "Sarcopenia", Lancet, 393, pp.2636~2646 (2019)
93. Cruz-Jentoft AJ, "Sarcopenia : revised European consensus on definition and diagnosis", Age Ageing, 48, pp.16~31 (2019)
94. Chen LK, "Asian Working Group for Sarcopenia : 2019 consensus update on sarcopenia diagnosis and treatment", J Am Med Dir Assoc, 21, pp.300~307 (2020)
95. McLean RR, "Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality : the foundation for the National Institutes of Health(FNIH)sarcopenia project", J Gerontol A Biol Sci Med Sci, 69, pp.576~583 (2014)
96. Fielding RA, "Sarcopenia : an undiagnosed condition in older adults. Current consensus definition : prevalence, etiology, and consequences. International working group on sarcopenia", J Am Med Dir Assoc, 12, pp.249~256 (2011)
97. Bhasin S, "Sarcopenia definition : the position statements of the sarcopenia definition and outcomes consortium", J Am Geriatr Soc, 68, pp.1410~1418 (2020)
98. Dent E, "International clinical practice guidelines for sarcopenia(ICFSR) : screening, diagnosis and management", J Nutr Health Aging, 22, pp.1148~1161 (2018)
99. Khosla S, "Bisphosphonate-associated osteonecrosis of the jaw : report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 22, pp.1479~1491 (2007)
100. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update", J Oral Maxillofac Surg, 72, pp.1938~1956 (2014)
101. Khan AA, "Diagnosis and management of osteonecrosis of the jaw : a systematic review and international consensus", J Bone Miner Res, 30, pp.3~23 (2015)
102. Beth-Tasdogan NH, "Interventions for managing medication-related osteonecrosis of the jaw", Cochrane Database Syst Rev, 7, pp.CD012432~ (2022)
103. Khan AA, "Case-based review of osteonecrosis of the jaw(ONJ)and application of the international recommendations for management from the international task force on ONJ", J Clin Densitom, 20, pp.8~24 (2017)

관련 논문AI추천